Bristol Myers Squibb presents first Phase 3 data on KarXT for Alzheimer’s psychosis
BMY•Bristol Myers Squibb presented first clinical data from two Phase 3 ADEPT studies evaluating KarXT for psychosis associated with Alzheimer’s disease. ADEPT-1 showed mean reductions of 1.9 points on the CGI-S score and 12.0 points on the NPI-C H+D scale; ADEPT-3 showed reductions of 0.8 and 5.1 points, respectively.
1. Study results
Bristol Myers Squibb presented first clinical data from two Phase 3 studies in the ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease. ADEPT-1 showed mean reductions of 1.9 points on the CGI-S score and 12.0 points on the NPI-C H+D scale, while ADEPT-3 showed mean reductions of 0.8 points on CGI-S and 5.1 points on NPI-C H+D.
2. Safety
KarXT was generally well tolerated across both studies, with no new safety signals identified.




